NDAORALCAPSULE
Approved
Apr 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
SOMA (carisoprodol) by Viatris (2) is identified. First approved in 1959.
Drug data last refreshed 8h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMA (carisoprodol) is an oral muscle relaxant approved in 1959 that works by altering interneuronal activity in the spinal cord and descending reticular formation to reduce muscle tension. It is indicated for acute musculoskeletal pain and is administered as an oral capsule.
$0.002BPart D
LOE ApproachingProduct is approaching loss of exclusivity with minimal Part D volume (1,605 claims in 2023), indicating a mature, declining asset with limited commercial infrastructure.
Mechanism of Action
identified. In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.
Pharmacologic Class:
Muscle Relaxant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Started Aug 2026
136 enrolled
VEXAS Syndrome
Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients
Started Jul 2026
120 enrolled
Invasive Fungal InfectionSolid Organ TransplantationOpportunistic Infections
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Started Jul 2026
428 enrolled
Talaromycosis
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Started Jun 2026
84 enrolled
Turner Syndrome
Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics
Started Jun 2026
500 enrolled
Severe Eosinophilic ACOS (Asthma-COPD Overlap)
Worked on SOMA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.